Enhanc3D Genomics expands leadership team with new COO

6 November 2023

Cambridge, UK-based Enhanc3D Genomics today announced the appointment of Hazel Jones as chief operating officer (COO).

Following a £10 million ($12.4 million) Series A financing in October 2022, Ms Jones’ appointment is the next step in the company’s drive to broaden the application of its technology and secure strategic collaboration agreements with pharmaceutical partners. The company is developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery.

In her new role, Ms Jones will lead scaling and growing the company’s global business operations. She will play an instrumental part in delivering the Enhanc3D’s strategy to commercial and academic partners. Her responsibilities also include long-term strategic planning of logistics and managing alliances with stakeholders.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK